2022
1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASE
Khatri R, Chhoda A, Sharma A, Farrell J, Ahuja N, Ehrlich A, Friedenberg F. 1147: DISPARITIES IN TIME TO TREATMENT INITIATION IN COLORECTAL CANCER IN THE US FROM 2004-2018: ANALYSIS OF THE NATIONAL CANCER DATABASE. Gastroenterology 2022, 162: s-270-s-271. DOI: 10.1016/s0016-5085(22)60641-3.Peer-Reviewed Original Research
2018
Genomics of Peritoneal Malignancies
Karunasena E, Sham J, McMahon KW, Ahuja N. Genomics of Peritoneal Malignancies. Surgical Oncology Clinics Of North America 2018, 27: 463-475. PMID: 29935683, DOI: 10.1016/j.soc.2018.02.004.Peer-Reviewed Original ResearchConceptsPeritoneal malignancyPeritoneal metastasisSimilar genetic mutationsEpithelial-mesenchymal transitionBiologic therapySurgical resectionMetastatic lesionsPredictive markerPrimary tumorIntraabdominal organsAggressive cancerMultiple cancersMetastasisMalignancyGenetic mutationsCancerOrgansResectionChemotherapyPeritoneumTherapyLesionsTumorsAbdomenAdjunctAutomated diagnosis of colon cancer using hyperspectral sensing
Beaulieu RJ, Goldstein SD, Singh J, Safar B, Banerjee A, Ahuja N. Automated diagnosis of colon cancer using hyperspectral sensing. International Journal Of Medical Robotics And Computer Assisted Surgery 2018, 14: e1897. PMID: 29479794, DOI: 10.1002/rcs.1897.Peer-Reviewed Original ResearchConceptsColorectal cancerPossible metastatic diseaseColorectal cancer detectionColorectal cancer reliesMultiple tumor typesMetastatic diseaseOperative resectionSurgical resectionPathologic evaluationSurgical managementCancer reliesTumor specimensColon specimensColon cancerTumor typesPatient specimensCancerResectionPatientsDiagnostic methodsTumorsCancer detectionDiagnostic technologiesContrast agents
2017
Mo1163 A Multicenter Study Evaluating Risk Factors of Lymph Node Metastasis in Early Gastric Cancer in the United States
Gutierrez O, Choi A, Draganov P, Khanna L, Sethi A, Bartel M, Abe S, Ali R, Park K, Melis M, Newman E, Hatzaras I, Hwang J, Reddy S, Farma J, Liu X, Schlachterman A, Kresak J, Gaddam S, Hanada Y, Montgomery E, Johnston F, Duncan M, Canto M, Ahuja N, Lennon A, Ngamruengphong S. Mo1163 A Multicenter Study Evaluating Risk Factors of Lymph Node Metastasis in Early Gastric Cancer in the United States. Gastrointestinal Endoscopy 2017, 85: ab444. DOI: 10.1016/j.gie.2017.03.1034.Peer-Reviewed Original Research
2016
O1-10-3 Associations of IGFBP3 SNPs, methylation and recurrence risk in patients with stage II colorectal cancer
Fu T, Li F, Ye J, Liu Z, Wolfgang C, Iacobuzio-Donahue C, Tong W, Liu B, Ahuja N. O1-10-3 Associations of IGFBP3 SNPs, methylation and recurrence risk in patients with stage II colorectal cancer. Annals Of Oncology 2016, 27: vii78. DOI: 10.1093/annonc/mdw521.016.Peer-Reviewed Original Research
2015
Early detection of pancreatic cancer.
Kim VM, Ahuja N. Early detection of pancreatic cancer. Chinese Journal Of Cancer Research 2015, 27: 321-31. PMID: 26361402, PMCID: PMC4560741, DOI: 10.3978/j.issn.1000-9604.2015.07.03.Peer-Reviewed Original ResearchPancreatic cancerPancreatic adenocarcinomaRisk factorsEarly detectionFourth common causeNew cancer casesGenetic risk factorsCancer deathCancer mortalityDefinitive curePrecursor lesionsCancer casesCommon causeWidespread screeningRisk-based strategyCancerNoninvasive methodGenetic mutationsMortal diseaseAdenocarcinomaCurrent standardDiseaseBest chanceClear needCausePersonalized Approaches to Gastrointestinal Cancers Importance of Integrating Genomic Information to Guide Therapy
He J, Ahuja N. Personalized Approaches to Gastrointestinal Cancers Importance of Integrating Genomic Information to Guide Therapy. Surgical Clinics Of North America 2015, 95: 1081-1094. PMID: 26315525, DOI: 10.1016/j.suc.2015.05.002.Peer-Reviewed Original ResearchConceptsGenetic testingPersonalized approachHigh-risk family membersCancer prevention strategiesComplex tumor heterogeneityTherapeutic decision makingProphylactic surgeryClinical trialsPrevention strategiesCancer behaviorGermline mutationsSuch personalized approachesTumor heterogeneityPatientsTherapyFamily membersBiopsySurgeryCancerCliniciansDifferent groupsTrialsAdaptive immune resistance in gastro-esophageal cancer: Correlating tumoral/stromal PDL1 expression with CD8 + cell count.
Kelly R, Thompson E, Zahurak M, Cornish T, Cuka N, Abdelfatah E, Taube J, Yang S, Duncan M, Ahuja N, Murphy A, Anders R. Adaptive immune resistance in gastro-esophageal cancer: Correlating tumoral/stromal PDL1 expression with CD8 + cell count. Journal Of Clinical Oncology 2015, 33: 4031-4031. DOI: 10.1200/jco.2015.33.15_suppl.4031.Peer-Reviewed Original ResearchA phase I trial of oral 5-azacitidine in combination with romidepsin in advanced solid tumors with an expansion cohort in virally mediated cancers and liposarcoma.
Reiss K, Rudek M, Sartorius-Mergenthaler S, Downs M, Cosgrove D, Gaillard S, Baylin S, Ahuja N, Azad N. A phase I trial of oral 5-azacitidine in combination with romidepsin in advanced solid tumors with an expansion cohort in virally mediated cancers and liposarcoma. Journal Of Clinical Oncology 2015, 33: tps2619-tps2619. DOI: 10.1200/jco.2015.33.15_suppl.tps2619.Peer-Reviewed Original ResearchA randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence.
Reiss K, Ahuja N, Baylin S, Mauro L, Linden S, White S, Laheru D, Herman J, Wolfgang C, Weiss M, Cameron J, Makary M, Azad N. A randomized phase II trial of epigenetic therapy following adjuvant treatment in patients with resected pancreatic cancer and high risk for recurrence. Journal Of Clinical Oncology 2015, 33: tps4144-tps4144. DOI: 10.1200/jco.2015.33.15_suppl.tps4144.Peer-Reviewed Original Research
2014
Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer.
Connolly R, Jankowitz R, Zahnow C, Zhang Z, Rudek M, Slater S, Powers P, Jeter S, Brufsky A, Piekarz R, Herman J, Ahuja N, Somlo G, Garcia A, Baylin S, Davidson N, Stearns V. Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer. Journal Of Clinical Oncology 2014, 32: 569-569. DOI: 10.1200/jco.2014.32.15_suppl.569.Peer-Reviewed Original ResearchFunctional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer
Wrangle J, Machida EO, Danilova L, Hulbert A, Franco N, Zhang W, Glöckner SC, Tessema M, Van Neste L, Easwaran H, Schuebel KE, Licchesi J, Hooker CM, Ahuja N, Amano J, Belinsky SA, Baylin SB, Herman JG, Brock MV. Functional Identification of Cancer-Specific Methylation of CDO1, HOXA9, and TAC1 for the Diagnosis of Lung Cancer. Clinical Cancer Research 2014, 20: 1856-1864. PMID: 24486589, PMCID: PMC4019442, DOI: 10.1158/1078-0432.ccr-13-2109.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerThree-gene panelLung cancerIndependent cohortPrimary NSCLC samplesCell lung cancerNSCLC cell linesNovel diagnostic biomarkersAdjuvant chemotherapyMolecular diagnostic testsCancer Genome AtlasCancer mortalityCancer-specific methylationSurgical specimensNSCLC samplesMolecular stagingEarly diagnosisDiagnostic biomarkersNormal tissuesDiagnostic testsCohortCancerGenome AtlasMethylation biomarkersCell lines
2013
The CpG Island Methylator Phenotype: What's in a Name?
Hughes LA, Melotte V, de Schrijver J, de Maat M, Smit VT, Bovée JV, French PJ, van den Brandt PA, Schouten LJ, de Meyer T, van Criekinge W, Ahuja N, Herman JG, Weijenberg MP, van Engeland M. The CpG Island Methylator Phenotype: What's in a Name? Cancer Research 2013, 73: 5858-5868. PMID: 23801749, DOI: 10.1158/0008-5472.can-12-4306.Peer-Reviewed Original ResearchConceptsCpG island methylator phenotypeTranslocation methylcytosine dioxygenase 2Tumor typesMethylator phenotypePrimary human astrocytesHuman neoplasiaIsocitrate dehydrogenase 1 (IDH1) mutationCpG island promoter methylationColorectal cancerOllier's diseaseAdrenocortical carcinomaProstate cancerMultiple enchondromasHuman astrocytesClinical practiceRenal cellsIDH2 mutationsCancer typesCancerDioxygenase 2Promoter methylationFunction mutationsMafucci's syndromeNeoplasiaLeukemia2564 resected periampullary adenocarcinomas at a single institution: trends over three decades
He J, Ahuja N, Makary MA, Cameron JL, Eckhauser FE, Choti MA, Hruban RH, Pawlik TM, Wolfgang CL. 2564 resected periampullary adenocarcinomas at a single institution: trends over three decades. Hepato Pancreato Biliary 2013, 16: 83-90. PMID: 23472829, PMCID: PMC3892319, DOI: 10.1111/hpb.12078.Peer-Reviewed Original ResearchConceptsPeriampullary adenocarcinomaBile ductSingle institutionPancreatic cancerIntraductal papillary mucinous neoplasmNumber of patientsPapillary mucinous neoplasmRelative survival ratesCurative intentWorse survivalLongterm outcomesMucinous neoplasmsSafe resectionLongterm survivalPathological diagnosisPrimary siteSurvival ratePancreaticoduodenectomyAdenocarcinomaPatientsSurvivalResectionSignificant differencesCancerDiagnosisDiscovery of early detection markers of pancreatic cancer and clinical application in blood-based screening
Kwak R, Keeley B, Guzzetta A, Jeschke J, Wolfgang C, Wang T, Herman J, Iacobuzio-Donahue C, Ahuja N. Discovery of early detection markers of pancreatic cancer and clinical application in blood-based screening. Pancreatology 2013, 13: e46. DOI: 10.1016/j.pan.2012.12.216.Peer-Reviewed Original ResearchDNA Methylation Biomarkers of Stool and Blood for Early Detection of Colon Cancer
Hong L, Ahuja N. DNA Methylation Biomarkers of Stool and Blood for Early Detection of Colon Cancer. Genetic Testing And Molecular Biomarkers 2013, 17: 401-406. PMID: 23406208, DOI: 10.1089/gtmb.2012.0478.Peer-Reviewed Original ResearchConceptsColon cancerDNA methylation markersEarly detectionMethylation markersStool-based testsCurrent screening testsScreening complianceColorectal cancerGeneral populationDNA methylation biomarkersClinical availabilityScreening testCancerClinical researchHigh efficacyBloodMethylation biomarkersStoolMarkersMore investigationEarly stagesColonoscopyPatientsMortalityDiseaseIs It Necessary to Follow Patients after Resection of a Benign Pancreatic Intraductal Papillary Mucinous Neoplasm?
He J, Cameron JL, Ahuja N, Makary MA, Hirose K, Choti MA, Schulick RD, Hruban RH, Pawlik TM, Wolfgang CL. Is It Necessary to Follow Patients after Resection of a Benign Pancreatic Intraductal Papillary Mucinous Neoplasm? Journal Of The American College Of Surgeons 2013, 216: 657-665. PMID: 23395158, PMCID: PMC3963007, DOI: 10.1016/j.jamcollsurg.2012.12.026.Peer-Reviewed Original ResearchConceptsIntraductal papillary mucinous neoplasmNoninvasive intraductal papillary mucinous neoplasmsPapillary mucinous neoplasmPancreatic cancerFamily historyMucinous neoplasmsNegative marginsInitial operationPancreatic intraductal papillary mucinous neoplasmsPartial pancreatic resectionMetastatic pancreatic adenocarcinomaInvasive pancreatic cancerRisk of developmentDegree of dysplasiaInitial surgeryMargin statusPancreatic resectionClose surveillanceInvasive adenocarcinomaPancreatic adenocarcinomaResectionPatientsCancerSurgeryAdenocarcinomaBlood-based screening for methylation changes in colorectal cancer patients using novel nanotechnologies.
Ahuja N, Kwak R, Keeley B, Stark A, Guzzetta A, Wolfgang C, Herman J, Iacobuzio-Donahue C, Wang T. Blood-based screening for methylation changes in colorectal cancer patients using novel nanotechnologies. Journal Of Clinical Oncology 2013, 31: 384-384. DOI: 10.1200/jco.2013.31.4_suppl.384.Peer-Reviewed Original ResearchNovel nanotechnologyBlood-based screeningColorectal cancer patientsColorectal cancer tissuesColorectal cancerCancer patientsCancer screeningCancer tissuesMethylation frequencyPrimary colorectal cancer tissuesColorectal cancer screeningBlood-based biomarkersSingle copy levelTumor DNA fragmentsNanotechnologyInvasive methodHigh sensitivityWhole bloodTissue samplesPlasma samplesCopy levelsSimilar frequencyPatientsCancerQuantitative PCR method
2012
Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen
Jeschke J, Van Neste L, Glöckner SC, Dhir M, Calmon MF, Deregowski V, Van Criekinge W, Vlassenbroeck I, Koch A, Chan TA, Cope L, Hooker CM, Schuebel KE, Gabrielson E, Winterpacht A, Baylin SB, Herman JG, Ahuja N. Biomarkers for detection and prognosis of breast cancer identified by a functional hypermethylome screen. Epigenetics 2012, 7: 701-709. PMID: 22647880, DOI: 10.4161/epi.20445.Peer-Reviewed Original ResearchConceptsPoor overall survivalBreast cancerOverall survivalPrognosis predictionEffective biomarkersClinical prognostic variablesPrimary breast cancerDetection of BCFrequent methylated genesStrongest single markersSignificant prognosticatorBC patientsValidation cohortPrognostic variablesPrognostic signatureEarly detectionCancerBiomarkersPromoter hypermethylationMethylation changesTumor heterogeneityPrognosisSingle markerGene expression approachSurvivalColorectal Cancer Stem Cells—Hype or Real?: Comment on “Combined CD133+/CD44+ Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer”
Ahuja N. Colorectal Cancer Stem Cells—Hype or Real?: Comment on “Combined CD133+/CD44+ Expression as a Prognostic Indicator of Disease-Free Survival in Patients With Colorectal Cancer”. JAMA Surgery 2012, 147: 24-25. PMID: 22250107, DOI: 10.1001/archsurg.2011.1218.Peer-Reviewed Original Research